Previous Play Slide ShowStop Slide Show Next
Carpentier-Edwards PERIMOUNT
Magna Ease Aortic Heart Valve

Where MAGNA hemodynamics
meets EASE of implantation.



The advanced Carpentier-Edwards PERIMOUNT Magna Ease aortic valve adds enhanced implantability to the unsurpassed hemodynamics1-7 of the Magna valve platform - setting the new standard for tissue valve performance.

Ease of implantation
  • Low profile eases insertion and aortotomy closure
  • Low stent base maximizes coronary ostia clearance
  • Sleek commissure posts ease insertion and enhance knot tying
  • Suture markers aid in valve orientation and suture placement
  • Contoured and compliant sewing ring provides an optimal anatomic fit
Proven superior hemodynamics
  • Industry-leading EOAs and low gradients documented in multiple published studies1-7
  • Based on a proven design with published hemodynamic stability up to 17 years post-implantation8
Designed for endurance
  • Built on the proven performance of PERIMOUNT aortic valves, with over 27 years of clinical experience9,10
  • The Carpentier-Edwards ThermaFix process* is the only anti-calcification technology designed to confront both major calcium binding sites


* No clinical data are available which evaluate the long-term impact of the Edwards Lifesciences tissue treatment in patients.


References
1. Dalmau MJ, González-Santos JM, López-Rodríguez J, et al. The Carpentier-Edwards Perimount Magna aortic xenograft: a new design with an improved hemodynamic performance. Int Cardiov Thorac Surg 2006;5:263-7.
2. Botzenhardt F, Eichinger WB, Guenzinger R, et al. Hemodynamic performance and incidence of patient-prosthesis mismatch of the complete supraannular Perimount Magna bioprosthesis in the aortic position. Thorac Cardiov Surg 2005;53:226-30.
3. Botzenhardt F, Eichinger WB, Bleiziffer S, et al. Hemodynamic comparison of bioprostheses for complete supra-annular position in patients with small aortic annulus. J Am Coll Cardiol 2005;45:2054-60.
4. Totaro P, Degno N, Zaidi A, et al. Carpentier-Edwards PERIMOUNT Magna bioprosthesis: a stented valve with stentless performance? J Thorac Cardiovasc Surg 2005;130:1668-74.
5. Dalmau MJ, González-Santos JM, López-Rodríguez J, et al. One year hemodynamic performance of the Perimount Magna pericardial xenograft and the Medtronic Mosaic bioprosthesis in the aortic position: a prospective randomized study. Int Cardiov Thorac Surg 2007;6:345-9.
6. Wagner IM, Eichinger WB, Bleiziffer S, et al. Influence of completely supra-annular placement of bioprostheses on exercise hemodynamics in patients with a small aortic annulus. J Thorac Cardiovasc Surg 2007;133:1234-41.
7. Borger MA, Nette AF, Maganti M, et al. Carpentier-Edwards Perimount Magna valve versus Medtronic Hancock II: a matched hemodynamic comparison. Ann Thorac Surg 2007;83:2054-9.
8. Banbury MK, Cosgrove DM, Thomas JD, et al. Hemodynamic stability during 17 years of the Carpentier-Edwards aortic pericardial bioprosthesis. Ann Thorac Surg 2002;73:1460-5.
9. Carpentier-Edwards PERIMOUNT aortic pericardial bioprosthesis 20-year results. Data on file at Edwards Lifesciences, 2003.
10. Aupart MR, Mirza A, Meurisse YA, et al. Perimount pericardial bioprosthesis for aortic calcified stenosis: 18-year experience with 1,133 patients. J Heart Valve Dis 2006;15:768-76.
For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse event.

Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.